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Background: Childhood dilated cardiomyopathy (DCM) has a high early mortality but late outcomes are uncertain.
Methods: The National Australian Childhood Cardiomyopathy Study is a longitudinal cohort study of all children in Australia with primary CM 
who presented at 0-10 years of age between 1987-1997. The prognostic factors sought included clinical presentation and results of relevant 
investigations, including serial echocardiography. Study end-points were death or transplantation.
Results: There were 184 patients with DCM. Of these, 9 (5%) children presented with sudden death and were not included in further analysis. 
Freedom from death/transplant (95% CI) was 74 (67-80)% 1 year after presentation, 62 (55-69)% at 10 years and 56 (46-65)% at 20 years. The 
table shows significant variables relating to outcome by multivariate analysis. 
Variables Hazard Ratio 95% CI p-value
Presenting age group* <0.001
Latest FS Z** 0.63 0.56, 0.71 <0.001
Change in FS Z/year** 0.77 0.67, 0.88 <0.001
* Those aged 0-4 weeks and those aged > 5 years had the worst outcomes; ** per unit increase in Z score.
Children with biopsy proven myocarditis had a better long-term survival than those with non-specific histology (100% vs 59%; p<.008). At latest 
follow-up 100 (96.2%) of surviving patients are symptom-free, 22 (21.2%) are receiving medications and 4 (3.8%) have had an ICD placed.
Conclusions: Mortality is greatest in the first year after presentation. The risk of death or transplant is related to age at presentation and severity 
of systolic dysfunction. Myocarditis diagnosed by biopsy confers a long-term survival advantage in childhood DCM.
